Doris M. Murray
Impact in
Papers in
- Oncology 4
- HER2/EGFR in Cancer Research 3
- Cancer Treatment and Pharmacology 2
- Cytokine Signaling Pathways and Interactions 1
-
- Lung Cancer Treatments and Mutations 2
- Co-authors
- Robert J. Mullin (3 shared papers)Barry R. Keith (3 shared papers)Karen Lackey (2 shared papers)Karen Affleck (2 shared papers)Wilson B. Knight (2 shared papers)David W. Rusnak (2 shared papers)Tona M. Gilmer (2 shared papers)Edgar R. Wood (2 shared papers)
- Journals
- Bioorganic & Medicinal Chemistry Letters (1 paper)Cancer Immunology Immunotherapy (1 paper)PubMed (2 papers)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Doris M. Murray
5 papers receiving 770 citations
Doris M. Murray's Hit Papers
Peers
Comparison fields: 5 of 63
- Oncology 472
- Genetics 71
- Radiology, Nuclear Medicine and Imaging 144
- Biotechnology 53
- Pulmonary and Respiratory Medicine 167
Countries citing papers authored by Doris M. Murray
This map shows the geographic impact of Doris M. Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris M. Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris M. Murray more than expected).
Fields of papers citing papers by Doris M. Murray
This network shows the impact of papers produced by Doris M. Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris M. Murray. The network helps show where Doris M. Murray may publish in the future.
Co-authors
The 25 scholars most cited alongside Doris M. Murray, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Hit paper breakdown → | 2001 | 592 |
| 2 | Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. | 1995 | 151 |
| 3 | 2003 | 41 | |
| 4 | 2003 | 8 | |
| 5 | Xenograft response to combination therapy with the ErbB1-ErbB2 tyrosine kinase inhibitor GW572016. | 2004 | 3 |
About Doris M. Murray
Doris M. Murray is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Organic Chemistry, Molecular Biology and Epidemiology, having authored 5 papers that have together received 795 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (3 papers), Lung Cancer Treatments and Mutations (2 papers), Cancer Treatment and Pharmacology (2 papers), Ubiquitin and proteasome pathways (1 paper), Cytokine Signaling Pathways and Interactions (1 paper), Monoclonal and Polyclonal Antibodies Research (1 paper), Microtubule and mitosis dynamics (1 paper) and Quinazolinone synthesis and applications (1 paper). The work is most often cited by research in Oncology (472 citations), Genetics (71 citations), Radiology, Nuclear Medicine and Imaging (144 citations), Biotechnology (53 citations) and Pulmonary and Respiratory Medicine (167 citations). Doris M. Murray has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Robert J. Mullin, Barry R. Keith, Karen Lackey, Karen Affleck, Wilson B. Knight, David W. Rusnak, Tona M. Gilmer, Edgar R. Wood, Krystal J. Alligood and Nelson Rhodes. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Immunology Immunotherapy and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.